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1. Introduction 
Hypothyroidism is a common endocrine disorder resulting from deficiency of thyroid 
hormone or its effects on peripheral tissues. It usually is caused by an insufficient 
production of thyroid hormone by thyroid gland (primary hypothyroidism), but it could be 
also caused by  inadequate secretion of either thyrotropin (ie. thyroid-stimulating hormone- 
TSH) from the pituitary gland (secondary hypothyroidism) or thyrotropin-releasing 
hormone (TRH) from the hypothalamus (tertiary hypothyroidism) (Bharaktiya, 2011). 
Mixedema (previously a sinonim for hypothyroidism) is reffered to a skin and subcutaneous 
tissue changes in severe hypothyroid patients.   
Hypothyroidism is a very common condition. It is estimated that about 2% of adult women 
and about 0,1-0,2% of men have clinical hypothyroidism, while the prevalence of subclinical 
disease is more frequent, up to 9% of adult population (Canaris et al., 2000; Danese et al., 
1996 ; Vanderpump et al., 1995). The incidence however increases with age (Bharaktiya, 
20111). The prevalence of hypothyroidism in newborns (congenital hypothyroidism) is 
about 1:3500 (LaFranchi, 1999).   
2. Causes of hypothyroidism 
The most common cause of hypothyroidism in adults may be summarised as follows 
(McPhee & Bauer, 1997): 
1. Congenital: 
a. aplasia, hypoplasia, thyroid ectopy  
b. defect of hormones’ synthesis and effects 
2. Acquired: 
a. autoimmune thyroiditis  
b. iodide deficient diet  
c. thyroid ablation (as a consequence of radiation, surgical interventions etc) 
3. Pharmacological: iodide, propylthiouracil, methimazole, lithium, thiocyanate etc 
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The most common cause of hypothyroidism in adults is autoimmune thyroid disease 
(AITD) where autoimmune thyroiditis (AT) is one of the entities. AT can begin suddenly or 
it can develop slowly over the years. The most frequent forms are Hashimoto’s thyroiditis 
and atrophic thyroiditis (American Thyroid Association, 2008). 
The second frequent cause is a thyroid ablation as a consequence of surgical removal of part 
or all of the gland in case of thyroid nodules, thyroid cancer, or Graves’ disease. If part of 
the gland is left, it may be able to make enough thyroid hormone to keep blood levels 
normal. It is necessary that at least 90% of the gland be destroyed in order to develop 
hypothyroidism (American Thyroid Association, 2008). 
Another cause of thyroid ablation is the radiation treatment during radiotherapy of neck for 
patients with Hodgkin’s lymphoma, or cancers of the head or neck, or the use of radioactive 
iodine (I-131) in some patients with Graves’ disease, nodular goiter, or thyroid cancer 
(American Thyroid Association, 2008). 
Third most common are all causes of congenital hypothyroidism (in newborns), where one 
could find newborns without a thyroid (aplasia) or with only a partly formed one 
(hypoplasia). There are also babies with partial or all thyroid tissue in the wrong place 
(ectopic thyroid) or in some cases the thyroid is in place, but biosynthetic enzymes are 
defective (American Thyroid Association, 2008). 
Although autoimmune thyroiditis is the most frequent cause of hypothyroidism, there are 
also a few forms of infective processes in thyroid. According to the duration, infective 
thyroiditis could be acute (generally caused by bacteria) or subacute (generally caused by 
viral agents). During the course of infective thyroiditis there could be a transient episode of 
thyroid hormones liberation in circulation from destroyed or damaged thyroid cells, called 
thyrotoxicosis. Subsequently if more than 90% of thyroid tissue is destroyed, 
hypothyroidism develops (McPhee & Bauer, 2007). 
In some cases, medicines could be the cause of hypothyroidism, usually by interfering with 
normal thyroid hormone synthesis. Very often it is found in patients taking  amiodarone, 
lithium, interferon alpha, and interleukin-2. These drugs are most likely to trigger 
hypothyroidism in patients who have a genetic tendency to develop AITD (American 
Thyroid Association, 2008). Potassium perchlorate could be used to treat thyrotoxicosis and 
hypothyroidism induced by amiodarone (Wolff, 1998). Perchlorate is a competitive inhibitor 
of the sodium-iodide symporter (NIS) that can suppress T3 and T4 production. Also, the 
drugs used for the hyperthyroidism treatment such as methimazole and propylthiouracil, 
could cause hypothyroidism.  
In 1998 it is estimated that about one third of world’s population lived in iodine-deficient 
areas, primarily in Africa, Southeast and Central Asia, but also in some European countries 
(like Germany, Belgium, France and Italy) (Dunn, 1996). Since iodine is the essential factor 
for thyroid hormone synthesis and it is concentrated in thyroid, any disequilibrium (too 
much or too little) in circulating iodine levels could cause or worsen hypothyroidism. Since 
more than 90% of dietary iodine is excreted in the urine, the World Health Organization 
(WHO) has determined 100mcg/L of urinary iodine as cut-off level for iodine deficiency 
(WHO, UNICEF & ICCID, 2001). In areas of the world with very low iodine intake in the 
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diet (like India, Chile, Ecuador, Himalayas), severe hypothyroidism can be seen in 5% to 
15% of the population (Mathur, 2011).  
If the pituitary or hypothalamus are damaged by a tumor, radiation, or surgery, 
hypothyroidism could be developed (secondary or tertiary hypothyroidism, respectively), 
characterized by diminished both, TSH and thyroid hormone levels. 
Finally, in some cases the deposit of abnormal substances in the thyroid, could be the cause 
of hypothyroidism. For example, in the course of amyloidosis there can be deposit of 
amyloid protein, in the course of sarcoidosis there can form granulomas, and in the course 
of hemochromatosis there can be deposit iron (American Thyroid Association, 2008) 
3. Pathogenesis of autoimmune thyroid disease (AITD) 
3.1 The role of genetic factors in the development of AITD 
It is generally believed that AITD is a complex of several entities that could overlap: 
Hashimoto’s thyroiditis (HT), Graves’ disease (GD) and orbitopathy. The majority of 
autoimmune endocrinopathies are inherited as complex genetic traits, with multiple genetic 
and environmental factors interactions which confer susceptibility to such disorders. The 
genetic factors remain largely unknown, with the exception of the human leukocyte antigen 
(HLA). It is known that AITD are more frequent in families with HLA DR3 and DR5 HLA 
alleles. Predominantly involved are women. Indeed, HT is 5 to 10 times more common in 
women than in men. Since the basis for autoimmune diseases may have a common origin, it 
is possible that patients with HT or their first degree relatives, have one or more other 
autoimmune diseases such as type 1 diabetes mellitus or pernicious anemia (with antibodies 
against gastric parietal cells or B12) (Mathur, 2011).  
In recent years however, considerable efforts have been made to discover other genetic 
factors responsible for autoimmune endocrinopathies (Vaidya & Pearce, 2004). There are 
several studies confirming that genetic polymorphism of the cytotoxic T lymphocyte antigen 
(CTLA)-4 alleles on 2q33 chromosome have been associated with HT (Awata et al., 1998; 
Donner et al., 1997; Nithiyananthan et al., 2002; Tomoyose et al., 2002). CTLA-4 is a co-
stimulatory molecule expressed on the surface of activated T cells (Brunet et al., 1987). 
CTLA-4 (49) A/G allele was significantly more frequent in the group of HT patients 
compared to the healthy controls. Additionally, linkage and association of CTLA-4 with the 
presence of thyroid antibodies have also been reported (Tomer et al., 2001; Zaletel et al., 
2002).  
3.2 Autoimmune mechanisms 
The thyroid is a major target for autoimmune disease, as exemplified by autoimmune 
thyroiditis (which include HT type 1 and 2, and atrophic thyroiditis), and GD with opposite 
clinical outcomes. Both diseases, but particularly HT, are characterized by lymphocytic 
infiltration of the gland which can result in tissue destruction, fibrosis and hypothyroidism. 
The follicular spaces shrink and colloid is absent or sparse. Fibrosis may be completely 
absent or present in degrees ranging from slight to moderate. Heuer and coll. (Bernet et al., 
1996; Heuer et al., 1996) found increased expression of IFN-gamma, IL-2 and CD25 positive 
T cells in the thyroid specimens of patients with HT.  
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Although the two disorders, HT and GD, have striking differences in clinical symptoms, 
they share the same histopathological features: lymphocytic infiltration and aberrant 
expression of HLA class II molecules on thyrocytes (Bernet et al., 1996). It is possible that HT 
and GD are caused by a similar immunologic dysfunction because similar autoantibodies 
(Abs) have been found in these patients.  
The cause of the autoimmune process is probably a combination of an inherited tendency 
and an as yet unknown trigger (American Thyroid Association, 2008). Previous studies have 
shown that HLA class II–expressing thyrocytes could stimulate the proliferation of 
autologous T cells grown from thyroid glands during autoimmune diseases (Dayan et al., 
1991; Londei et al., 1984; Weetman et al., 1986). Local up-regulation of the antigen-
presenting function on thyrocytes may be an early event in the development of AITD 
(Dayan et al., 1991). Autoantigen presentation by thyrocytes is more efficient than by 
professional antigen-presenting cells (APC), because the thyroid autoantigens thyroid 
peroxidase and thyrotropin (TSH) receptor are membrane proteins. These proteins can be 
recycled and presented by class II molecules, and the effective concentration of these 
antigens on thyroid epithelial cells may be higher than when picked up by other antigen-
presenting cells (Feldmann et al., 1992). However, lack of expression of costimulators such 
as B7.1 (CD80) or B7.2 (CD86) by thyrocytes undermines their ability to present antigens. 
Instead, class II–expressing thyrocytes may induce tolerance in autoreactive CD4+T cells 
(Matsuoka et al., 1996). 
On the other hand,  increased  expression  of  intercellular  adhesion molecule-1 (ICAM-1)  
has  been  shown  present  in  specimens  from patients  with  HT,  while  expression  was 
less  or  absent  in  GD  (Bagnasco  et  al.,  1991;  Ciampolillo  et  al.,  1993;  Pesce  et  al.,  
2002; Weetman  et  al.,  1990).  ICAM-1 is a member of the Ig gene superfamily and present 
on the surface of various cell types, serves as a ligand for lymphocyte function associated 
antigen-1 (LFA-1), and can be induced by various stimuli, such as cytokines (IL-1, tumor 
necrosis factor [TNF]-alpha, interferon [IFN]-gamma), hormones, cellular stresses (H2O2), 
and other environmental factors (Roebuck & Finnegan, 1999). Upon up-regulation it 
promotes cell–cell interactions, providing intense signals to the immune system that cause 
the T cells to home in on the inflamed site (Bonita et al., 2002). 
An  earlier  investigation  had  found  that  elevated  (rather  than  reduced) plasma  levels  of  
soluble  CTLA-4  (sCTLA-4)  protein  were  more frequent  in  patients with AITD than in  
healthy  controls  (Oaks  &  Hallett, 2000). CTLA-4 molecule,  together with CD28  co-
stimulatory molecule (both expressed on the  T cell  surface), plays  a critical role  in the  T cell 
response to antigen  presentation. For T cell activation  two signals  are needed: TCR engages 
antigen (the first signal), which is bound to a HLA class II molecule on the surface of an APC, 
and a co-stimulatory signal, that could be stimulatory or inhibitory.  This stimulatory second 
signal is provided mainly  by the  interaction of  CD28  with  its ligands, B7.1 (CD80) and B7.2 
(CD86)  on APC.  CTLA-4 also binds to the same B7 ligands (CD80 and CD86) but it delivers 
inhibitory signals to T-cell activation  (Walunas et al., 1994). In the absence of  a stimulatory 
second signal,  the antigen–TCR engagement is ineffective, and causes functional  inactivation 
of the T cell (anergy) or induces apoptosis of the cell  (Alegre et al., 2001).  
Soluble  CTLA4  molecules  (sCTLA4),  more  frequently  found  in  AITD patients,  could  
compete  with  membrane-bound  CTLA-4  for  CD80 / CD86-binding  sites  and  cause  a  
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reduction  of  inhibitory  signaling (Vaida  &  Pearce,  2004).  Thus,  autoreactive  T   cells  
will  become activated  leading  to  autoimmune  process.  The  altered  levels  of  sCTLA-4  
could  lead to either  blockade of  available  B7  ligands,  leading to  a  decreased  
stimulatory  signal (if  sCTLA-4  is  increased),  or  to  an inability  of  membranous  CTLA-4  
to  bind  the  B7 ligand,  leading  to subsequently  less  inhibitory  signal  (if  sCTLA-4  is  
decreased). 
3.3 The possible role of iodide excess on thyroid mild inflammation and the 
development of hypothyroidism  
Many epidemiological studies have demonstrated the toxic effects of iodide excess on 
thyroid function. In one study, about 10% of European  patients receiving 0.5 mg of iodide 
per day  for 6 months developed  lymphocytic infiltration of the thyroid gland, accompanied  
by  hypothyroidism  or  less often hyperthyroidism. Both the infiltration and the 
hypofunction were reversible upon discontinuation of iodide (Kahaly et al., 1998). The 
thyroid response to excess iodide is known as thyroid autoregulation. Most commonly, 
studies that examined the effects of toxic doses of iodide were usually performed in Fisher’s 
rat thyroid low-serum-5 (FRTL-5) cells, which can synthesize and secrete thyroglobulin (Tg), 
absorb and transport iodide, and produce thyroid peroxidase (Ambesi-Impiombato et al., 
1980). Although iodide doses over 10 mM caused toxic effects on the thyroid gland in vivo 
(Li & Boyages, 1994), higher concentrations of iodide were needed in order to influence cell 
proliferation (Becks et al., 1987; Eng et al., 2001; Smerdely et al., 1993) or even to induce 
apoptosis (Smerdely et al., 1993; Vitale et al., 2000) in cell culture.  
Possible sources of excess iodide for humans are: amiodarone, povidone-iodine, iodinated 
radiographic contrast media, Lugol’s 5% solution (used as 0,1-0,3ml for the treatment of 
simple goiter, equivalent of 12,5-37,5 mg of iodine) (Gennaro, 1995), dry or powdered algae 
(in many vitamin-mineral supplements and preparations for weight-loosing programs and 
herbal products).  
The U.S.  recommended  daily  intake  (RDI)  for  dietary  iodine  is  150 mcg for adults,  220 
mcg for pregnant women, and 270 mcg during lactation (Surks et al., 2004).  The safe upper  
limit  has  been  set  at  1,000 mcg (1 mg)  as  a result of studies assessing TSH levels with 
supplementation.  Iodine intake over 1 mg daily could potentially contribute to an 
underlying thyroid pathology-AITD, or even could exacerbate nodularities in euthyroid 
individuals in those taking over 20 mg of iodide (Burgi et al., 2001; Dunn et al., 1998; 
Robison et al., 1998). Population studies have shown that an excess of  iodine  intake  may  
increase  the  prevalence  of  autoimmune thyroiditis  (HT and atrophic thyroiditis)  in  
animals  and  humans, increasing  the  risk  of  clinically evident hypothyroidism (Teng et 
al., 2006).  
Iodide excess could influence thyroid cell growth and immunological profile. It is known that 
Lugol’s solution given a couple of days before surgery in GD patients reduced HLA class I and 
II mRNA expression in thyroid cells in vivo and in vitro (Schuppert et al., 1996). It has also 
been reported that ICAM-1 mRNA was doubled in suspensions of isolated human thyroid 
follicles incubated with 10 mM sodium iodide (NaI) (Yamazaki et al., 2003). Furthermore, 
iodide excess did not change Tg level in FRTL-5 cells (Pregliasco et al., 1996), but it inhibited 
iodine organification  (Davies et al., 1989), thyroid hormone secretion (Sato et al., 1990), and 
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cAMP production and secretion  (Miyazaki et al., 1999) in isolated human thyroid follicles. 
Recently, it was reported (Kostic et al., 2009) that iodide excess inhibited human primary 
thyroid cell proliferation and gradually increased ICAM-1 on cell surface. In the presence of 
low-dose IFN-gamma, KI additionally augmented ICAM-1 expression, and such effect could 
induce lymphocytic infiltration in the thyroid gland and secretion of proinflammatory 
cytokines. Decreased Tg production in the presence of KI excess and IFN-gamma could 
explain the development of hypothyroidism after iodide dietary addition in patients that 
already have lymphocytic infiltration and/or mild inflammation in the thyroid gland. 
Among the subjects exposed to iodine supplementation for the prevention of iodine 
deficiency or fed diet with high iodine intake, besides a few cases of focal and reversible 
lymphocyte infiltration of the thyroid, severe cases of hypothyroidism, not reversed by the 
suspension of iodine administration, with severe lymphocyte infiltration and parenchymal 
destruction have been described. 
Various animal strains genetically susceptible to autoimmune thyroiditis have been 
described, such as Cornell and obese strain (OS) chickens, BB/Worcester and Buffalo rats, 
and diabetic non-obese mice NOD.H-2h4. 
NOD mice expressing the H-2Jg7 allele of MHC class II, are genetically predisposed to 
develop type I diabetes and other autoimmune diseases, such as spontaneous autoimmune 
thyroiditis, which appears with low incidence. On the contrary, transgenic mice NOD.H-
2h4, expressing the H-2Ak allele on the NOD background, do not develop diabetes but 
develop, with higher frequency, a spontaneous autoimmune thyroiditis (SAT). Moreover, as 
in BB/Worcester rats, SAT is increased by the addition of iodide in the drinking water. In 
these animals, deletion of IFN-gamma is associated with a strong reduction of anti-TG 
antibodies and of thyroid infiltration with B, T and plasma cells. 
High iodide doses transiently inhibit Tg iodination by thyroperoxidase (TPO) (Wolff-
Chaikoff effect). This is because, at high iodide to Tg ratios (mM to microM), iodide 
peroxidation to molecular iodine (I2) by TPO prevails over iodination of tyrosyl residues of 
Tg (Km 6 x 10-3M and 8 x 10-5, respectively). The iodination of tyrosyl residues leads to the 
production of one mole of OH- ions per mole of tyrosyl residue formed, whereas the 
peroxidation of iodide to I2 leads to the formation of two moles of OH- ions per mole of I2 
produced. Hydrogen peroxide (H2O2), produced by the NADPH-oxidase of the apical 
membrane of thyroid epithelial cells (TECs), is the limiting electron acceptor in the TPO-
catalized reactions. Its production leads to the production of superoxide anion (O2-) as an 
intermediate. Excess I- ions inhibit both the enzymatic degradation of H2O2 by TPO and 
non enzymatic oxidation of H2O2 by I2.  
However, in dog thyroid slices, iodide excess seems to inhibit H2O2 generation, through the 
formation of oxidized iodine compounds. Thus, excess iodide inhibits thyroid functions by 
multiple mechanisms, which include, besides true anion effects, the oxidative modification 
and/or iodination of important enzymes, the inhibitory effect of the products of the 
iodination or peroxidation of polyunsaturated fatty acid, which, in turn, can act as free 
radicals. An imbalanced production of free radicals and/or dysfunctions of enzymes 
involved in their detoxication, such as glutathione peroxidase, catalase and superoxide 
dismutase, have been associated with aging, neurodegenerative diseases, cancer and 
autoimmune diseases. 
www.intechopen.com
 
Causes of Hypothyroidism 
 
157 
At persistingly high doses, iodide can determine thyroid involution. Preliminary studies 
showed the accumulation of lipid peroxidation products, with necrosis and inflammation of 
murine and human thyroid exposed to toxic iodide doses (23, 24). More recently, it has been 
demonstrated that thyroid cell apoptosis is the prevalent cause of TEC death in thyroid 
iodide-dependent involution in goitrogen-treated rats. However, TEC necrosis induced by 
iodide excess has been indicated as a preliminary step in a model of the development of 
autoimmune thyroiditis.  
Iodide excess induces apoptosis in thyroid cultured cells, through a p53-independent 
oxidative mechanism. Diminished levels of bcl-2 gene expression and increased levels of bax 
gene expression have been found in the brain and the thyroid of guinea-pigs exposed to 
excess iodide. In OS chickens, the TEC damage, preceding the development of autoimmune 
thyroiditis, is mediated by the production of ROS. H2O2 induces apoptosis in cultured pig 
thyroid cells. 
Cellular products of thyroid iodinated lipids include arachidonic acid derivatives, such as 6-
iodo-5-hydroxy-8,11,14-eicosatrienoic acid and 14-iodo-15-hydroxy-5,8,11 eicosatrienoic acid 
(I-OH-A), and their respective delta and omega iodolactones (IL-d and IL-ω). IL-ω inhibits 
iodide organification in dog thyroid slices, by inhibiting H2O2 production (31). IL-ω and IL-
d inhibit the proliferation of rat FRTL-5 cultured thyroid cells and cause the involution of 
thyroid in goitrogen-treated rats. IL-d inhibits inositol-3-phosphate production and EGF and 
beta FGF signal transduction in human and pig thyroid cells. 2-iodoesadecanal (2-IHDA), 
produced from the rat thyroid exposed to iodide, inhibits adenylate cyclase activity and 
cAMP-stimulated activities of NADPH oxidase and TPO. The non-iodinated products 
derived from arachidonic acid oxidation induce apoptosis in smooth muscle vessel cells. 4-
Hydroxynonenal, the most important product of arachidonic acid oxidation, induces 
apoptosis in a number of cell types, including endotelial cells. As with iodide in the thyroid, 
it can do so through a p53-idependent mechanism 
The current vision of the pathogenesis of autoimmunity favors the triggering role of the 
exposure of cryptic self epitopes. It has been demonstrated that a hormonogenic carboxy-
terminal fragment of Tg , beginning at residue 2384, was released during enzymatic 
iodination or metal-catalyzed oxidation of Tg in vitro, as well as during oxidative stress in 
vivo. Because it was recognized by autoantibodies of patients affected with autoimmune 
thyroid disease (AITD), it was suggested that oxidative proteolysis can expose 
immunopathogenetic cryptic epitopes. 
In vitro iodination of murine Tg , used to immunize susceptible rats, determined the 
transformation of a T-cell epitope (residues 2495-2511) from cryptic to immunodominant in 
vivo. It is well known that the iodination of Tg with TPO in vitro is accompanied by the 
formation of proteolytic peptides, whose amount is related to their iodine and hormone 
content. 
Thyroid autoantigens could be also transferred to thyroidal dendritic cells (DC) and cross-
presented to T lymphocytes. Apoptosis of TECs, induced by iodide excess, could play a 
pivotal role in this process. Apoptotic cells are a preferred source of antigens for cross-
presentation, being captured by DCs via alpha(v)-beta5 or alpha(v)-beta 5 integrins and 
CD36. Although DC can cross-present both apoptotic and necrotic cells, MHC class II-
restricted presentation can occur with both of them, while MHC class I-restricted 
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presentation can only occur with apoptotic cells. Moreover, even if immature DCs 
phagocytose efficiently both apoptotic and necrotic cells, the exposition to the latter is 
necessary in order to induce their maturation to APC, with optimal abilities of antigen 
processing and presentation and elevate levels of CD38, DC-LAMP, and CD40 and CD86 co-
stimulatory molecules. Moreover, DC can cross-activate CTL by the internalization of heat 
shock proteins gp96 and Hsp70 loaded with antigenic peptides. Finally, the processing and 
the class II-restricted presentation are increased by receptor-mediated internalization of 
mannosylated antigens, such as Tg. 
3.4 Other cell stressors that could induce hypothyroidism 
It has  been  shown  that  human  primary  thyroid  cells  increase  HLA-DR surface  
expression  in  response  to  a variety of   cell stressors,  such  as  IFN-gamma  (Montani et 
al.,  1998;  Otten et al.,  1998;  Wu et al.,  1999)  and ionizing radiations (Czirjak et al., 1990) or 
transiently modify  HLA-DR expression in vitro in the presence of iodide excess (Kostic et 
al.,  2009). Recently,  Kostic et al. (Kostic et al.,  2010)  showed  that  HLA-DR expression was 
also transiently increased  24 hours after  UVC  treatment of human primary thyroid cells in 
vitro, and subsequently returned to normal level 48 h after irradiation. This local up-
regulation of antigen presenting function on thyrocytes in vivo could be sustained by a local 
inflammatory network (formed by cytokines and other cells of the immune system) and it 
may be an early event in the development of AITD  (Botazzo et al., 1983; Liu et al., 2008).  
Another consequence of UVC as physical mutagen is a cell cycle arrest or apoptosis 
induction in human primary thyroid cells. As already mentioned, the local up-regulation of 
HLA-DR by thyrocytes together with the expression of proteins from apoptotic cells may 
represent an early event in the development of AITD (Botazzo et al., 1983).  
The model for the cellular response of human thyroid cells after UVC irradiation (Kostic et 
al., 2010) suggested that UV induced dimers lead to activation of p53 that is in turn able to 
induce G0 / G1 cell cycle arrest in order to repair DNA damage. Cells that are able to repair 
damaged DNA or that do not have a large DNA damage enter S phase of the cell cycle, but 
secondary lesions generated during replication, induce apoptosis. The cells that are severely 
damaged after UVC irradiation, diminish Bcl-2 expression in the mitochondria and start 
apoptosis. 
It has also been shown that in microgravity conditions the thyroid cells FRTL5 in culture do 
not respond to TSH treatment and present an irregular shape with condensed chromatin, a 
modification of the cell membrane with shedding of the TSH-receptor in the culture 
medium, and an increase of sphingomyelin-synthase and bax proteins. It is possible that 
microgravity induces a rearrangement of specific sections of the cell membrane, which act as 
platforms for molecular receptors, thus influencing thyroid cell function in astronauts 
during space missions. 
It has been recently reported that FTRL-5 cells cultured in the presence or absence of TSH in 
the International Space Mission during the Eneide and Experia missions presented a similar 
cell growth pattern, which indicates an absence of response to TSH in space (Albi et al., 
2010). It is difficult to establish whether this modification that occurs in space is due to 
cosmic radiation or microgravity. 
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It was previously reported that simulated weightlessness changed the cytoskeleton of 
normal thyroid cells (Infanger et al., 2004), increased the extracellular matrix proteins 
(Infanger et al., 2006), reduced thyroglobulin, FT3 and FT4 secretion, (Grimm et al., 2002), 
and induced apoptosis (Kossmehl et al., 2002, Grimm et al., 2002) of thyroid carcinoma cells. 
These data were supported by exposing mitochondria-rich thyroid carcinoma cells and 
normal thyroid cells to simulated microgravity conditions and obtaining apoptotic cells 
(Kossmehl et al., 2003). We reported for the first time the modifications of thyroid cells 
under real microgravity conditions. 
We have shown that, in microgravity, the FRTL5 cells appeared aggregated and presented 
chromatin condensation, the TSH-induced cAMP production was significantly attenuated, 
and the TSHR was increased about 4.4 fold in the culture medium. At Earth's gravity, the 
TSHR was unaltered, and the cells responded to TSH treatment with normally high levels of 
cAMP production (Albi et al., 2011). 
It is possible that the loss of TSHR from the cells in microgravity was due to the 
disorganization of microdomains within the cell membrane, depending on Sphingomyelin 
and Cholesterol incorporation from the culture medium that yielded a more rigid 
membrane structure. These data were consistent with the observation that a medium 
lacking TSH caused cessation of FRTL-5 cell proliferation due to the decrease in membrane 
lipid fluidity, which in turn was caused by an absolute increase of membrane cholesterol. 
It has been shown that microgravity induced the FRTL5 cells treated with TSH to release 
Cholesterol and Sphingomyelin to the culture medium probably by modifying the 
microdomain structure (Albi et al., 2011). The lower amount of TSHR in the culture medium 
after TSH stimulation with respect to the TSH- samples may have been due to the fact that 
raft-TSHR complexes are regulated by TSH, which stimulates the formation of monomers 
and allows their rapid exit from the rafts (Latif et al., 2003). Therefore, the modification of 
lipid rafts consequent to the removal of Cholesterol and Sphingomyelin may have been 
preceded by a transfer of the receptor, which would explain the reduction but not the 
absence of the cAMP response. The disorganization of microdomains in microgravity was 
confirmed by the presence of caveolin 1 in the pellet obtained after fixation, which was 
absent in the samples maintained in Earth's gravity. 
4. Types of AITD 
The types of AITD may be summarised as follows: 
 Type 1 (Thyroiditis chronica Hashimoto type 1): 
 euthyroidism with anti-TPO Abs and 
 1A: with goiter; 
 1B: without goiter 
 Type 2 (Thyroiditis chronica Hashimoto type 2): 
 hypothyroidism with anti-TPO Abs and 
 2A with goiter; 2B without goiter; 
 2C transitory forms (postpartal hypothyroidism, Hashitoxicosis) 
 Type 3 (Morbus Graves): 
 3A hyperthyroidism with 
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 stimulating anti-TSH R Abs;  
 anti-TPO Abs and anti-Tg Abs +/- 
 3B Euthyroidism with supressed TSH and anti-TSH R Abs 
 3C Hypothyroidism. Orbitopathy and anti-TPO Abs +/– 
The Abs present in the sera of patients with AITD are only the witnesses of autoimmune 
destruction or activation of thyroid gland.  
The most frequent in HT are Abs against thyroperoxidase (anti-TPO), Abs associated with 
euthyroidism (HT type 1) or hypothyroidism (HT type 2) and accompanied or not by goiter. 
On the other hand, in GD (AITD type 3) Abs against Tg (anti-Tg Abs) in AITD type 3A, and 
stimulating or inhibiting Abs against TSH receptor (anti-TSHR Abs) may also be found.  
According to the prevalence of stimulating or blocking anti-TSHR Abs, GD patients could 
develop hyperthyroidism (stimulating anti-TSHR Abs), hypothyroidism (inhibiting anti-
TSHR Abs) or be euthyroid (GD type 3B). 
Of great interest is the relationship between Interferon and Autoimmune Thyroid Disease. 
Three different types of thyroid dysfunction associated with IFN treatment have been 
reported: (1) autoimmune (often subclinical) hypothyroidism; (2) destructive thyroiditis; 
and (3) Graves' hyperthyroidism. 
These abnormalities can occur at any time during IFN therapy, from as early as 4 weeks 
until as late as 23 months after initiation, and there is no clear difference between the three 
types, with a median date of onset of 17 weeks after start of IFN treatment. Pooling of 
several studies shows that hypothyroidism seems to be more frequent than thyrotoxicosis. 
The majority of patients with hypothyroidism also have TPO antibodies (87%), indicating 
the autoimmune nature of this event. According to most studies hypothyroidism can be 
transient, subsiding after discontinuation of IFN. In a large Italian survey, hypothyroidism 
was, however, permanent in 59% of the patients. A similar result was found in the review of 
the literature (Koh et al.), which showed that 56% of the patients had permanent 
hypothyroidism. In a recent long-term follow-up study, it was found (Carella et al.) that 10 
of 36 (28%) TPO antibody-positive patients lost their antibodies at 6 years after 
discontinuation. On the other hand, 26 patients remained antibody-positive at that time, and 
subclinical hypothyroidism was detected in seven of them 
5. Conclusion 
Hypothyroidism is a common endocrine disorder resulting from deficiency of thyroid 
hormone. It usually is a primary process in which the thyroid gland produces insufficient 
amounts of thyroid hormone. It can also be secondary—that is, lack of thyroid hormone 
secretion due to inadequate secretion of either thyrotropin (ie, thyroid-stimulating hormone 
[TSH]) from the pituitary gland or thyrotropin-releasing hormone (TRH) from the 
hypothalamus (secondary or tertiary hypothyroidism). The patient's presentation may vary 
from asymptomatic to, rarely, coma with multisystem organ failure (myxedema coma). 
Localized disease of the thyroid gland that results in decreased thyroid hormone production 
is the most common cause of hypothyroidism. 
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The most common cause of hypothyroidism in adults is autoimmune thyroid disease (AITD. 
The second frequent cause is a thyroid ablation as a consequence of surgical removal of part 
or all of the gland. Third most common are all causes of congenital hypothyroidism (in 
newborns). There are also a few forms of infective processes in thyroid. 
In some cases, medicines could be the cause of hypothyroidism, usually by interfering with 
normal thyroid hormone synthesis. 
Because all metabolically active cells require thyroid hormone, deficiency of the hormone 
has a wide range of effects. Systemic effects are due to either derangements in metabolic 
processes or direct effects by myxedematous infiltration (ie, accumulation of 
glucosaminoglycans in the tissues). 
The myxedematous changes in the heart result in decreased contractility, cardiac 
enlargement, pericardial effusion, decreased pulse, and decreased cardiac output. In the GI 
tract, achlorhydria and decreased intestinal transit with gastric stasis can occur. Delayed 
puberty, anovulation, menstrual irregularities, and infertility are common. Decreased 
thyroid hormone effect can cause increased levels of total cholesterol and low-density 
lipoprotein (LDL) cholesterol and a possible change in high-density lipoprotein (HDL) 
cholesterol due to a change in metabolic clearance. In addition, hypothyroidism may result 
in an increase in insulin resistance.  
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